Introduction {#s1}
============

Pregnancy represents a unique immunological state in which the immune system of the mother undergoes adaptations that allow her to tolerate the semi-allogenic conceptus ([@B1]--[@B3]). Indeed, pregnancy is divided into three different immunological stages based on cytokine profiles ([@B4]). Pioneer studies indicated that, while the innate immune system is upregulated to protect the mother against infection and the fetus from rejection ([@B5], [@B6]), the adaptive immune response toward paternal/fetal antigens seems to be selectively suppressed \[i.e., driven toward a T-helper (Th)2-like phenotype\] ([@B7]--[@B11]). Specifically, the cellular components of the innate immune system in the maternal systemic circulation are activated as evidenced by increased numbers of monocytes and granulocytes ([@B12], [@B13]). Such innate immune cells display an activated phenotype, comparable to that observed in women with sepsis ([@B13]), and exhibit enhanced functionality (phagocytosis, respiratory burst activity, and cytokine production) ([@B14]--[@B18]). The humoral components of the innate immune system are also boosted during pregnancy ([@B5]). For example, complement components and acute phase proteins are increased in the circulation of pregnant women ([@B19]--[@B24]). In contrast to the innate immune system, the cellular (e.g., T cells and B cells) and humoral (e.g., antibodies) components of the adaptive immune system in the maternal circulation during normal pregnancy have received less attention.

The systemic intravascular inflammatory response during normal pregnancy is especially activated in women who experience the physiological process of labor at term ([@B18], [@B25]) and in those who undergo pregnancy complications such as preterm labor ([@B18], [@B26], [@B27]), preterm premature rupture of membranes ([@B28]), and preeclampsia ([@B13], [@B17], [@B29]--[@B32]). Therefore, the systemic immune response reflects both physiological and pathological processes, and the early detection of these changes may lead to the discovery of non-invasive biomarkers for obstetrical disease.

Herein, for the first time, we aimed to provide a roadmap of the modulations in the cellular transcriptome in maternal circulation during normal pregnancy. In addition, we assessed whether gestational mRNA changes of the cellular transcriptome correlate to those of the plasma proteome during normal pregnancy.

Materials and Methods {#s2}
=====================

Study Design
------------

We conducted a prospective longitudinal study that enrolled women attending the Center for Advanced Obstetrical Care and Research of the Perinatology Research Branch, NICHD/NIH/DHHS; the Detroit Medical Center, and Wayne State University School of Medicine. Based on this cohort, we designed a retrospective study that included 49 women with normal pregnancy who delivered at term and had 4--6 blood samples collected throughout gestation \[median number of samples = 5, interquartile range (IQR) = 5--6\] (*n* = 282). Blood samples were collected at the time of a prenatal visit, scheduled at 4-week intervals from the first or early second trimester until delivery in the following gestational age intervals: 8- \<16, 16- \<24, 24- \<28, 28- \<32, 32- \<37, and \>37 weeks. All patients provided written informed consent and the use of biological specimens, as well as clinical and ultrasound data, for research purposes were approved by the Institutional Review Boards of Wayne State University and NICHD. All experiments were performed in accordance with relevant guidelines and regulations.

RNA Extraction
--------------

RNA was isolated from PAXgene® Blood RNA collection tubes (BD Biosciences, San Jose, CA; Catalog \#762165), as described in the PAXgene® Blood miRNA Kit Handbook. Purified RNA was quantified by UV spectrophotometry using the DropSense96® Microplate Spectrophotometer (Trinean, Gentbrugge, Belgium), and quality was assessed by microfluidics using the RNA ScreenTape on the Agilent 2200 TapeStation (Agilent Technologies, Wilmington, DE, USA).

Microarray Analysis
-------------------

RNA was processed and hybridized to GeneChip™ Human Transcriptome Arrays 2.0 (P/N 902162) according to the Affymetrix GeneChip™ WT Pico Reagent Kit Users Guide (P/N 703262 Rev. 1) as follows: Biotinylated cDNA were prepared from 20--50 ng total RNA. Labeled cDNA were hybridized to the arrays in a GeneChip™ Hybridization Oven 640 by rotating at 60 rpm, 45°C for 16 h. Arrays were then washed and stained in the Affymetrix Fluidics Station 450 and scanned using the Affymetrix 3000 7G GeneChip™ Scanner with Autoloader. Raw intensity data were generated from array images using the Affymetrix AGCC software.

Data Analysis
-------------

### Preprocessing

Affymetrix Human Transcriptome Arrays CEL files were preprocessed using Robust Multi-array Average (RMA) ([@B33]) implemented in the *oligo* package ([@B34]) and annotation from the *hta20sttranscriptcluster.db* package of Bioconductor ([@B35]). Since samples were profiled in several batches as a part of a larger study, correction for potential batch effects was performed using the *removeBatchEffect* function of the *limma* package in *Bioconductor*. After batch effect correction, data from the sample collected at the time of labor from the 21 women who had spontaneous term labor were removed to avoid confounding gestational age-related changes with those due to the onset of labor at term. The final analysis set of 261 transcriptomes was used in downstream analyses described below.

### Expression Calling

Transcript clusters (typically one or two per unique gene) were deemed present in a given sample if one of its probesets (targeting a specific exon) was expressed above background (*p*-value for expression above background p~DBAG~ \<0.05) determined using the Transcriptome Analysis Console (version 4.0) (ThermoFisher Scientific). Genes were retained if deemed present in \>25% of the 261 samples.

### Differential Expression

Expression profiles were visually inspected to determine consistency of the data in sequential samples collected from the same woman. One of 261 samples consistently had the lowest value for a large fraction of the genes and was deemed as outlier and removed from further analysis. Linear mixed-effects models ([@B36]) were then used to fit log~2~ gene expression data as a function of gestational age (continuous) and included cubic polynomial terms of gestational age as fixed effects and a random intercept term for each woman. Significance *p*-values for the association of gene expression and gestational age were determined using likelihood ratio tests between a model with and without gestational age terms. A False Discovery Rate adjusted *p*-value (*q*-value) \<0.1 and a fold change (FC) of \>1.25 were required for significance. Fold change was determined as the ratio of the highest vs. lowest average expression from 10 to 40 weeks of gestation. Linear mixed-effects models were fit using the *lmer* function, while the likelihood ratio tests were performed using the *anova* function available in the *lme4* R package ([@B36]).

### Gene Ontology and Pathway Analysis

Gene ontology and pathway analysis was conducted using a hypergeometric test on Gene Ontology (GO) ([@B37]) and Developmental FunctionaL Annotation at Tufts (DFLAT) databases ([@B38]), as well as on Curated Gene Sets (C2) collection from the Molecular Signatures Database (MSigDB) database ([@B39]). In addition, enrichment tests were performed for tissue specificity and chromosomal locations of genes. Tissue-specific genes were defined as those with median expression 30 times higher in a given tissue than the median expression of all other tissues documented in the Gene Atlas ([@B40]) as previously described ([@B41]).

Unless otherwise stated, all enrichment analyses were based on a hypergeometric test and accounted for multiple testing with *q* \< 0.05 being considered a significant result. In all enrichment analyses, the background gene list was defined as the compendium of genes deemed present in \>25% of the samples.

### Changes in Cell-Type Specific mRNA Signatures With Gestational Age

In this analysis, we tested whether previously reported cell-type specific mRNA signatures derived by single-cell RNA-Seq studies of placenta tissues ([@B42]) were modulated with advancing gestation in normal pregnancy. The 13 cell types identified by Tsang et al. ([@B42]) were: B cells, T cells, monocytes, cytotrophoblasts, syncytiotrophoblast, decidual cells, dendritic cells, endothelial cells, erythrocytes, Hofbauer cells, stromal cells, vascular smooth muscle cell, and extravillous trophoblasts. The mRNA signatures for these cell types were first quantified in each patient sample by averaging expression data over genes part of each signature. Before averaging, the data for each gene was first standardized by subtracting the mean and dividing by standard deviation of expression across term samples (\>37 weeks). Cell-type specific expression averages were then fit as a function of gestational age using linear mixed-effects models, as described above for the analysis of data of individual genes.

### Assessment of mRNA Protein Correlations

Maternal plasma abundance of 1,125 proteins in 71 samples collected from 16 of the women included in the current study were obtained from the S1 File of Erez et al. ([@B43]). The correlation between each mRNA and corresponding protein pair was assessed by fitting linear mixed-effects models with the response being the protein abundance and the predictor being the mRNA expression. These models included a random intercept term to account for the repeated observations from the same subject. The meaning of the mRNA coefficient in this model is change in log~2~ protein abundance for one unit change in log~2~ gene expression. The significance of the protein---mRNA correlation was assessed by the t-score for the regression line slope, and false discovery rate adjustment of resulting *p*-values was performed across all mRNA-protein pairs that were tested. A q-value \<0.1 was considered a significant result.

Results {#s3}
=======

Longitudinal Patterns of the Cellular Transcriptome Throughout Normal Pregnancy
-------------------------------------------------------------------------------

The mRNA profiles of longitudinal maternal blood samples were determined at exon level resolution by microarrays. The characteristics of the study population are shown in [Table 1](#T1){ref-type="table"}. A total of 26,458 protein-coding mRNA transcript clusters were expressed above background levels in at least 25% of the samples, as were 5,706 non-coding RNA transcript clusters. Analysis of longitudinal expression patterns identified 614 transcript clusters (510 coding and 104 non-coding) with significant expression modulation during gestation (*q* \< 0.1 and minimum fold change of 1.25) ([Supplementary File 1](#SM1){ref-type="supplementary-material"}, [Supplementary Figure 1](#SM2){ref-type="supplementary-material"}). Significant transcripts were found on all chromosomes; yet, more differentially expressed transcripts than expected were observed on chromosome 14 (51/614 transcript clusters, odds ratio = 3.5, *p* \< 0.0001; [Figure 1](#F1){ref-type="fig"}), with 28/51 differentially expressed genes on this chromosome being annotated to immune processes. Chromosome 14 includes genes of critical importance for immunity ([@B44]); therefore, these data show that pregnancy has a strong effect on the maternal immune system.

###### 

Demographic characteristics of the women included in the study.

  **Characteristics**                   **Median (IQR) or % (*n*)**
  ------------------------------------- -----------------------------
  Age (years)                           25 (21--28)
  Prepregnant BMI (kg/m^2^)             25.8 (22.5--30.9)
  Nulliparity (%)                       32.7% (16)
  Race (%)                              
   African American                     91.8% (45)
   White                                4.1% (2)
   Other                                4.1% (2)
  Gestational age at delivery (weeks)   39.3 (38.6--39.9)
  Route of delivery                     
   Vaginal delivery                     53.1%(26)
   Cesarean delivery                    46.9% (23)
  Birth weight (grams)                  3,285 (3,050--3,495)

*Continuous data are presented as median \[Interquartile Range (IQR)\] and categorical data as percentage (number). BMI, body mass index*.

![Chromosomal location of genes modulated throughout normal pregnancy. The outer circle represents the different chromosomes while the inner histograms show the number of differentially expressed genes binned by the genomic location within each chromosome. Chromosome 14 was the most enriched in differentially expressed genes throughout normal pregnancy (gray rectangle).](fimmu-10-02863-g0001){#F1}

To define clusters of expression trajectories during gestation, we focused on 112 of the 614 significant transcript clusters that changed more than 1.5-fold from 10 to 40 weeks of gestation. Three distinct clusters of expression modulation emerged: genes that (1) steadily increased throughout gestation (89 genes; [Figure 2](#F2){ref-type="fig"}, red cluster), (2) steadily decreased throughout gestation (12 genes; [Figure 2](#F2){ref-type="fig"}, green cluster), and (3) decreased prior to mid-gestation followed by an increase (11 genes; [Figure 2](#F2){ref-type="fig"}, blue cluster). These results indicate that the expression of the most highly modulated genes increases with advancing gestational age.

![Clustering of average gene expression profiles throughout normal pregnancy. Average profiles of genes that change throughout normal pregnancy and have a fold change \>1.5 were clustered using hierarchical clustering. The distance metric used in the clustering was 1-Pearson correlation. Three clusters were identified: Cluster 1 (red, 89 genes), Cluster 2 (green, 12 genes), and Cluster 3 (blue, 11 genes). Note that, in this figure, the average gene expression profiles vs. gestational age were reset so that their value is 0 at 10 weeks of gestation.](fimmu-10-02863-g0002){#F2}

Of note, the 19 mRNA transcript clusters (corresponding to 16 unique genes) that changed more than 2-fold in expression during pregnancy all increased from 10 to 40 weeks of gestation ([Figure 3](#F3){ref-type="fig"}, gray lines correspond to individual pregnancies and blue lines show the average expression). The expression of these 16 genes increased from early to late pregnancy and tended to plateau near term, with the exception of 2 genes (interferon-induced protein 27 and 44-like) ([Figure 3](#F3){ref-type="fig"}). Several of these most highly modulated genes are related to host immune response (e.g., *MMP8, DEFA1B*, and *DEFA4*) ([@B45], [@B46]), again emphasizing the immune response adaptations during normal pregnancy.

![Genes changing in expression \>2-fold from 10 to 40 weeks of gestation. Gray lines represent log~2~ normalized gene expression in 4--6 samples for each of the 49 women. Blue lines correspond to the average expression determined by a polynomial fit by linear mixed-effects models.](fimmu-10-02863-g0003){#F3}

Biological Processes, Pathways, and Immune Cell Signatures Associated With Advancing Gestation in Normal Pregnancy
------------------------------------------------------------------------------------------------------------------

We performed gene ontology enrichment analysis to interpret the changes in gene expression occurring throughout gestation. We identified 157 biological processes modulated during gestation, which included *cellular and humoral immunity, defense response, response to external biotic stimulus* (e.g., bacteria and viruses), *regulation of lipid storage, interleukin-1beta production and secretion*, and *erythrocyte development*, among others ([Table 2](#T2){ref-type="table"}). An additional 134 biological processes altered during gestation were found when querying the Developmental FunctionaL Annotation at Tufts (DFLAT) database, such as *stress response, immune system development, cytokine response*, and *regulation of angiogenesis* ([Table 3](#T3){ref-type="table"}).

###### 

Gene ontology biological processes enriched in genes differentially expressed with gestational age.

  **Biological process**                                                                                                                             **Count**   **Size**   **Odds ratio**   ***q***
  -------------------------------------------------------------------------------------------------------------------------------------------------- ----------- ---------- ---------------- ---------
  Immune system process                                                                                                                              176         2,520      4.4              0.000
  Immune response                                                                                                                                    128         1,580      4.6              0.000
  Defense response                                                                                                                                   125         1,736      3.9              0.000
  Regulation of immune system process                                                                                                                103         1,470      3.6              0.000
  Innate immune response                                                                                                                             85          1,063      4                0.000
  Regulation of immune response                                                                                                                      74          956        3.8              0.000
  Immune effector process                                                                                                                            61          740        3.9              0.000
  Positive regulation of immune system process                                                                                                       65          886        3.5              0.000
  Response to external biotic stimulus                                                                                                               63          845        3.5              0.000
  Response to other organism                                                                                                                         63          845        3.5              0.000
  Defense response to other organism                                                                                                                 47          515        4.3              0.000
  Response to biotic stimulus                                                                                                                        63          879        3.4              0.000
  Positive regulation of immune response                                                                                                             49          639        3.5              0.000
  Humoral immune response                                                                                                                            24          178        6.4              0.000
  Immune response-regulating signaling pathway                                                                                                       47          631        3.4              0.000
  Immune response-activating signal transduction                                                                                                     38          459        3.8              0.000
  Activation of immune response                                                                                                                      40          510        3.6              0.000
  Lymphocyte mediated immunity                                                                                                                       25          217        5.3              0.000
  Immune response-regulating cell surface receptor signaling pathway                                                                                 39          499        3.5              0.000
  Hemopoiesis                                                                                                                                        48          708        3.1              0.000
  Immune response-activating cell surface receptor signaling pathway                                                                                 30          315        4.3              0.000
  Leukocyte mediated immunity                                                                                                                        28          285        4.5              0.000
  Adaptive immune response                                                                                                                           30          332        4.1              0.000
  Response to bacterium                                                                                                                              37          481        3.5              0.000
  Defense response to bacterium                                                                                                                      23          211        5                0.000
  Complement activation, classical pathway                                                                                                           10          43         12               0.000
  Hemoglobin metabolic process                                                                                                                       7           17         27.6             0.000
  Defense response to virus                                                                                                                          26          313        3.7              0.000
  Regulation of viral genome replication                                                                                                             12          69         8.4              0.000
  Response to virus                                                                                                                                  29          391        3.3              0.000
  Complement activation                                                                                                                              11          61         8.7              0.000
  Phagocytosis                                                                                                                                       20          209        4.3              0.000
  Fc-gamma receptor signaling pathway                                                                                                                13          90         6.7              0.000
  Adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains                          20          215        4.1              0.000
  Immunoglobulin mediated immune response                                                                                                            14          112        5.7              0.000
  B cell mediated immunity                                                                                                                           14          115        5.5              0.000
  Defense response to fungus                                                                                                                         8           34         12.2             0.000
  Immune response-regulating cell surface receptor signaling pathway involved in phagocytosis                                                        12          86         6.5              0.000
  Fc-gamma receptor signaling pathway involved in phagocytosis                                                                                       12          86         6.5              0.000
  Humoral immune response mediated by circulating immunoglobulin                                                                                     10          58         8.3              0.000
  Cell killing                                                                                                                                       13          103        5.8              0.000
  Fc receptor signaling pathway                                                                                                                      26          364        3.1              0.000
  Cellular defense response                                                                                                                          10          59         8.1              0.000
  Protoporphyrinogen IX metabolic process                                                                                                            5           10         39.3             0.000
  Viral genome replication                                                                                                                           12          89         6.2              0.000
  Porphyrin-containing compound metabolic process                                                                                                    8           36         11.3             0.000
  Modification of morphology or physiology of other organism                                                                                         12          90         6.1              0.000
  Antibacterial humoral response                                                                                                                     9           48         9.1              0.000
  Receptor-mediated endocytosis                                                                                                                      21          260        3.5              0.000
  Fc receptor mediated stimulatory signaling pathway                                                                                                 12          92         6                0.000
  Killing of cells of other organism                                                                                                                 7           27         13.8             0.000
  Disruption of cells of other organism                                                                                                              7           27         13.8             0.000
  Type I interferon signaling pathway                                                                                                                11          78         6.5              0.000
  Cellular response to type I interferon                                                                                                             11          78         6.5              0.000
  Response to type I interferon                                                                                                                      11          79         6.4              0.000
  Antimicrobial humoral response                                                                                                                     9           53         8.1              0.000
  Regulation of symbiosis, encompassing mutualism through parasitism                                                                                 18          213        3.7              0.000
  Protein activation cascade                                                                                                                         11          84         6                0.000
  Tetrapyrrole metabolic process                                                                                                                     9           56         7.6              0.000
  Response to fungus                                                                                                                                 8           47         8.1              0.000
  Extrinsic apoptotic signaling pathway                                                                                                              18          229        3.4              0.000
  Antigen receptor-mediated signaling pathway                                                                                                        14          147        4.2              0.000
  Iron ion homeostasis                                                                                                                               11          95         5.2              0.001
  Porphyrin-containing compound biosynthetic process                                                                                                 6           25         12.4             0.001
  Cytokine secretion                                                                                                                                 14          152        4                0.001
  Positive regulation of leukocyte activation                                                                                                        19          265        3.1              0.001
  Positive regulation of viral genome replication                                                                                                    6           27         11.2             0.001
  Regulation of macrophage derived foam cell differentiation                                                                                         6           28         10.7             0.001
  Tetrapyrrole biosynthetic process                                                                                                                  6           28         10.7             0.001
  Regulation of response to reactive oxygen species                                                                                                  6           28         10.7             0.001
  Regulation of response to oxidative stress                                                                                                         8           55         6.7              0.001
  Regulation of viral process                                                                                                                        15          188        3.5              0.001
  Cytolysis                                                                                                                                          6           30         9.8              0.001
  Negative regulation of multi-organism process                                                                                                      13          148        3.8              0.001
  Natural killer cell mediated immunity                                                                                                              8           58         6.3              0.001
  Negative regulation of extrinsic apoptotic signaling pathway                                                                                       10          92         4.8              0.002
  Macrophage derived foam cell differentiation                                                                                                       6           31         9.4              0.002
  Regulation of bone resorption                                                                                                                      6           31         9.4              0.002
  Foam cell differentiation                                                                                                                          6           31         9.4              0.002
  T cell receptor signaling pathway                                                                                                                  11          114        4.2              0.002
  Regulation of viral life cycle                                                                                                                     14          176        3.4              0.002
  Transition metal ion homeostasis                                                                                                                   12          135        3.9              0.002
  Erythrocyte differentiation                                                                                                                        10          99         4.4              0.003
  Hydrogen peroxide catabolic process                                                                                                                5           23         10.9             0.003
  Positive regulation of leukocyte mediated immunity                                                                                                 9           83         4.8              0.003
  Positive regulation of lymphocyte mediated immunity                                                                                                8           67         5.3              0.003
  Regulation of cellular response to oxidative stress                                                                                                7           51         6.3              0.003
  Negative regulation of viral process                                                                                                               9           85         4.7              0.004
  Regulation of bone remodeling                                                                                                                      6           37         7.6              0.004
  Myeloid cell development                                                                                                                           7           52         6.1              0.004
  Negative regulation of cysteine-type endopeptidase activity involved in apoptotic process                                                          9           87         4.6              0.004
  Erythrocyte homeostasis                                                                                                                            10          106        4.1              0.004
  Erythrocyte development                                                                                                                            5           25         9.8              0.004
  Regulation of lipid storage                                                                                                                        6           39         7.1              0.005
  Negative regulation of cysteine-type endopeptidase activity                                                                                        9           90         4.4              0.005
  Response to interferon-gamma                                                                                                                       12          154        3.3              0.006
  Antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent                                                    8           74         4.8              0.006
  Interaction with host                                                                                                                              12          155        3.3              0.006
  Heme metabolic process                                                                                                                             5           28         8.5              0.006
  Respiratory burst                                                                                                                                  5           28         8.5              0.006
  Regulation of extrinsic apoptotic signaling pathway                                                                                                12          157        3.3              0.006
  Interleukin-1 beta secretion                                                                                                                       5           29         8.2              0.007
  Antigen processing and presentation of exogenous peptide antigen via MHC class I                                                                   8           78         4.5              0.008
  Hydrogen peroxide metabolic process                                                                                                                6           44         6.2              0.008
  Negative regulation of viral genome replication                                                                                                    6           45         6                0.008
  Leukocyte mediated cytotoxicity                                                                                                                    8           81         4.3              0.009
  Negative regulation of viral life cycle                                                                                                            8           82         4.3              0.010
  Response to transition metal nanoparticle                                                                                                          10          123        3.5              0.010
  Interaction with symbiont                                                                                                                          6           47         5.7              0.010
  Myeloid cell homeostasis                                                                                                                           10          125        3.4              0.011
  Interleukin-1 secretion                                                                                                                            5           33         7                0.012
  Bone resorption                                                                                                                                    6           49         5.5              0.012
  Positive regulation of immune effector process                                                                                                     11          150        3.1              0.013
  Negative regulation of signal transduction in absence of ligand                                                                                    5           34         6.8              0.013
  Negative regulation of extrinsic apoptotic signaling pathway in absence of ligand                                                                  5           34         6.8              0.013
  Interferon-gamma-mediated signaling pathway                                                                                                        8           87         4                0.013
  Interleukin-1 beta production                                                                                                                      6           51         5.2              0.014
  T cell costimulation                                                                                                                               7           71         4.3              0.016
  Nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway                                                               6           53         5                0.016
  Negative regulation of epithelial cell proliferation                                                                                               9           112        3.4              0.016
  Lymphocyte costimulation                                                                                                                           7           72         4.2              0.017
  Negative regulation of I-kappaB kinase/NF-kappaB signaling                                                                                         6           54         4.9              0.018
  Defense response to Gram-positive bacterium                                                                                                        7           73         4.2              0.018
  Modification of morphology or physiology of other organism involved in symbiotic interaction                                                       7           74         4.1              0.019
  Cofactor biosynthetic process                                                                                                                      10          139        3.1              0.020
  Regulation of antigen receptor-mediated signaling pathway                                                                                          5           39         5.8              0.021
  Regulation of tissue remodeling                                                                                                                    6           57         4.6              0.022
  Lipid storage                                                                                                                                      6           60         4.4              0.026
  Interleukin-1 production                                                                                                                           6           60         4.4              0.026
  Positive regulation of NF-kappaB transcription factor activity                                                                                     9           123        3.1              0.026
  Antigen processing and presentation of peptide antigen via MHC class I                                                                             8           101        3.4              0.026
  Regulation of transforming growth factor beta receptor signaling pathway                                                                           8           102        3.3              0.028
  Regulation of cellular response to transforming growth factor beta stimulus                                                                        8           102        3.3              0.028
  Signal transduction in absence of ligand                                                                                                           7           81         3.7              0.028
  Extrinsic apoptotic signaling pathway in absence of ligand                                                                                         7           81         3.7              0.028
  Regulation of lymphocyte mediated immunity                                                                                                         8           105        3.2              0.031
  Positive regulation of cytokine secretion                                                                                                          7           84         3.6              0.032
  Alpha-beta T cell activation                                                                                                                       8           107        3.2              0.033
  Positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains   6           66         3.9              0.036
  Macrophage activation                                                                                                                              5           48         4.6              0.039
  Regulation of extrinsic apoptotic signaling pathway in absence of ligand                                                                           5           48         4.6              0.039
  Natural killer cell activation                                                                                                                     6           68         3.8              0.039
  Protein K48-linked ubiquitination                                                                                                                  5           49         4.5              0.040
  Positive regulation of adaptive immune response                                                                                                    6           69         3.7              0.041
  Cellular iron ion homeostasis                                                                                                                      6           71         3.6              0.045
  Cholesterol transport                                                                                                                              6           71         3.6              0.045
  Negative regulation of transforming growth factor beta receptor signaling pathway                                                                  6           71         3.6              0.045
  Negative regulation of cellular response to transforming growth factor beta stimulus                                                               6           71         3.6              0.045
  Regulation of cofactor metabolic process                                                                                                           5           51         4.3              0.045
  Regulation of coenzyme metabolic process                                                                                                           5           51         4.3              0.045
  Regulation of transcription factor import into nucleus                                                                                             7           93         3.2              0.045
  Sterol transport                                                                                                                                   6           72         3.6              0.046
  Bone remodeling                                                                                                                                    6           72         3.6              0.046
  Regulation of cytokine biosynthetic process                                                                                                        7           94         3.2              0.046
  Transcription factor import into nucleus                                                                                                           7           94         3.2              0.046
  Positive regulation of inflammatory response                                                                                                       7           94         3.2              0.046
  Response to zinc ion                                                                                                                               5           52         4.2              0.047

*Count, number of differentially expressed genes annotated to the category; Size, Number of expressed genes assigned to the category. Odds ratio, Enrichment odds ratio by Fisher\'s exact (hypergeometric) test; q, false discovery rate adjusted p-value. Values displayed as 0.000 should be interpreted as \<0.0005*.

###### 

DFLAT biological processes enriched in genes differentially expressed with gestational age.

  **DFLAT biological process**                                                                      **Count**   **Size**   **Odds ratio**   ***q***
  ------------------------------------------------------------------------------------------------- ----------- ---------- ---------------- ---------
  Response to stress                                                                                138         2,632      3.4              0.000
  Homeostatic process                                                                               44          785        3.2              0.000
  Response to cytokine                                                                              35          542        3.7              0.000
  Immune system development                                                                         36          618        3.4              0.000
  Cellular response to cytokine stimulus                                                            31          492        3.6              0.000
  Regulation of defense response                                                                    35          609        3.3              0.000
  Hematopoietic or lymphoid organ development                                                       34          590        3.3              0.000
  Cytokine-mediated signaling pathway                                                               27          404        3.8              0.000
  Regulation of multi-organism process                                                              25          403        3.5              0.000
  Regulation of cytokine production                                                                 25          415        3.4              0.000
  Myeloid cell differentiation                                                                      17          206        4.8              0.000
  Endocytosis                                                                                       20          297        3.8              0.000
  Regulation of innate immune response                                                              22          358        3.5              0.000
  Homeostasis of number of cells                                                                    11          99         6.6              0.000
  Cytokine production                                                                               9           64         8.6              0.000
  Positive regulation of defense response                                                           19          321        3.3              0.000
  Fc-epsilon receptor signaling pathway                                                             18          298        3.4              0.000
  Regulation of defense response to virus                                                           13          169        4.4              0.000
  Regulation of response to biotic stimulus                                                         14          201        4                0.000
  Regulation of immune effector process                                                             18          315        3.2              0.000
  Apoptotic signaling pathway                                                                       16          261        3.5              0.000
  Regulation of apoptotic signaling pathway                                                         15          240        3.5              0.001
  Response to transforming growth factor beta                                                       11          137        4.6              0.001
  Leukocyte migration                                                                               13          188        3.9              0.001
  Positive regulation of innate immune response                                                     16          271        3.3              0.001
  Regulation of peptidase activity                                                                  16          273        3.3              0.001
  Cell cycle arrest                                                                                 10          117        4.9              0.001
  Blood circulation                                                                                 13          194        3.8              0.001
  Circulatory system process                                                                        13          195        3.8              0.001
  Negative regulation of apoptotic signaling pathway                                                10          122        4.7              0.001
  Organic anion transport                                                                           15          260        3.2              0.001
  Regulation of endopeptidase activity                                                              15          263        3.2              0.001
  Protein maturation                                                                                12          183        3.7              0.001
  Secretion by cell                                                                                 15          272        3.1              0.002
  Cellular response to transforming growth factor beta stimulus                                     10          135        4.2              0.002
  Regulation of hemopoiesis                                                                         11          162        3.8              0.002
  Antigen processing and presentation of exogenous peptide antigen                                  11          165        3.8              0.002
  Antigen processing and presentation of exogenous antigen                                          11          165        3.8              0.002
  Transforming growth factor beta receptor signaling pathway                                        9           115        4.5              0.002
  Pigment metabolic process                                                                         5           33         9.3              0.002
  Inflammatory response                                                                             10          142        4                0.002
  Protein polyubiquitination                                                                        11          169        3.7              0.002
  Regulation of leukocyte activation                                                                14          256        3.1              0.002
  Positive regulation of lymphocyte activation                                                      11          170        3.6              0.002
  Regulation of carbohydrate metabolic process                                                      8           94         4.9              0.002
  Regulation of lymphocyte activation                                                               13          227        3.2              0.002
  Cellular response to interferon-gamma                                                             8           96         4.8              0.003
  Antigen processing and presentation of peptide antigen                                            11          175        3.5              0.003
  Regulation of cysteine-type endopeptidase activity                                                11          175        3.5              0.003
  Negative regulation of endopeptidase activity                                                     10          150        3.8              0.003
  Cellular transition metal ion homeostasis                                                         7           78         5.2              0.004
  Protein homooligomerization                                                                       9           127        4                0.004
  Negative regulation of cytokine production                                                        10          154        3.7              0.004
  Negative regulation of peptidase activity                                                         10          155        3.6              0.004
  Protein secretion                                                                                 6           58         6                0.004
  Tumor necrosis factor-mediated signaling pathway                                                  9           131        3.9              0.004
  Response to tumor necrosis factor                                                                 11          187        3.3              0.004
  Positive regulation of sequence-specific DNA binding transcription factor activity                11          188        3.3              0.005
  Antigen processing and presentation                                                               11          190        3.2              0.005
  Regulation of lymphocyte proliferation                                                            8           109        4.2              0.005
  Regulation of cysteine-type endopeptidase activity involved in apoptotic process                  10          163        3.4              0.005
  Cell redox homeostasis                                                                            5           42         7.1              0.005
  Regulation of mononuclear cell proliferation                                                      8           110        4.1              0.005
  Positive regulation of cell activation                                                            11          193        3.2              0.005
  Positive regulation of protein serine/threonine kinase activity                                   11          195        3.1              0.006
  Regulation of cellular carbohydrate metabolic process                                             7           87         4.6              0.006
  Positive regulation of T cell activation                                                          9           140        3.6              0.006
  Regulation of leukocyte proliferation                                                             8           114        4                0.006
  Positive regulation of hemopoiesis                                                                7           89         4.5              0.007
  Regulation of leukocyte differentiation                                                           8           115        3.9              0.007
  Protein processing                                                                                10          171        3.3              0.007
  Positive regulation of leukocyte cell-cell adhesion                                               9           143        3.5              0.007
  Cellular response to tumor necrosis factor                                                        10          172        3.2              0.007
  Leukocyte activation involved in immune response                                                  7           91         4.4              0.007
  Positive regulation of homotypic cell-cell adhesion                                               9           144        3.5              0.007
  Cell activation involved in immune response                                                       7           93         4.3              0.008
  Regulation of intrinsic apoptotic signaling pathway                                               7           96         4.1              0.009
  Regulation of T cell activation                                                                   10          180        3.1              0.009
  positive regulation of lymphocyte proliferation                                                   6           74         4.6              0.010
  Reactive oxygen species metabolic process                                                         6           74         4.6              0.010
  Positive regulation of peptidyl-serine phosphorylation                                            5           52         5.6              0.011
  Positive regulation of mononuclear cell proliferation                                             6           75         4.6              0.011
  Regulation of epithelial cell proliferation                                                       9           157        3.2              0.011
  Male gonad development                                                                            7           101        3.9              0.011
  Development of primary male sexual characteristics                                                7           101        3.9              0.011
  Positive regulation of leukocyte proliferation                                                    6           77         4.4              0.012
  Retina homeostasis                                                                                5           54         5.3              0.012
  Transmembrane receptor protein serine/threonine kinase signaling pathway                          9           162        3.1              0.013
  Positive regulation of cell-cell adhesion                                                         9           163        3.1              0.014
  Myotube differentiation                                                                           5           56         5.1              0.014
  Regulation of interleukin-8 production                                                            5           56         5.1              0.014
  Positive regulation of cell cycle arrest                                                          6           83         4.1              0.016
  Negative regulation of intrinsic apoptotic signaling pathway                                      5           59         4.8              0.017
  Positive regulation of transmembrane transport                                                    6           84         4                0.017
  Positive regulation of defense response to virus by host                                          7           112        3.5              0.017
  Plasma membrane organization                                                                      8           142        3.1              0.018
  Regulation of nucleocytoplasmic transport                                                         8           143        3.1              0.019
  Response to molecule of bacterial origin                                                          7           114        3.4              0.019
  Positive regulation of stress-activated MAPK cascade                                              6           87         3.9              0.019
  Positive regulation of MAP kinase activity                                                        8           144        3.1              0.019
  Regulation of angiogenesis                                                                        8           145        3.1              0.019
  Negative regulation of establishment of protein localization                                      8           145        3.1              0.019
  Positive regulation of stress-activated protein kinase signaling cascade                          6           88         3.8              0.020
  Stimulatory C-type lectin receptor signaling pathway                                              7           116        3.4              0.020
  Regulation of lymphocyte differentiation                                                          5           63         4.5              0.020
  Innate immune response activating cell surface receptor signaling pathway                         7           117        3.3              0.020
  Intrinsic apoptotic signaling pathway                                                             7           117        3.3              0.020
  Positive regulation of apoptotic signaling pathway                                                7           117        3.3              0.020
  Organic hydroxy compound transport                                                                6           90         3.7              0.021
  Notch signaling pathway                                                                           6           91         3.7              0.022
  Regulation of defense response to virus by host                                                   7           120        3.2              0.022
  Response to reactive oxygen species                                                               6           94         3.6              0.025
  Xenophagy                                                                                         6           95         3.5              0.026
  Male sex differentiation                                                                          7           124        3.1              0.026
  Establishment of protein localization to plasma membrane                                          5           69         4.1              0.027
  Positive regulation of leukocyte differentiation                                                  5           69         4.1              0.027
  Lymphocyte activation involved in immune response                                                 5           71         4                0.029
  Mitochondrial membrane organization                                                               5           71         4                0.029
  Regulation of peptidyl-serine phosphorylation                                                     5           71         4                0.029
  Response to UV                                                                                    6           99         3.4              0.030
  Negative regulation of cellular protein localization                                              6           102        3.3              0.033
  Organic acid transmembrane transport                                                              5           75         3.7              0.035
  Regulation of cell cycle arrest                                                                   6           104        3.2              0.035
  Activation of cysteine-type endopeptidase activity involved in apoptotic process                  5           76         3.7              0.036
  Positive regulation of binding                                                                    5           77         3.6              0.038
  Regulation of T cell proliferation                                                                5           78         3.6              0.040
  Positive regulation of ion transmembrane transport                                                5           79         3.5              0.041
  Negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway   5           80         3.5              0.043
  Platelet degranulation                                                                            5           81         3.4              0.044
  Activation of cysteine-type endopeptidase activity                                                5           82         3.4              0.046
  Negative regulation of cytoplasmic transport                                                      5           82         3.4              0.046
  Tissue homeostasis                                                                                5           83         3.4              0.048
  Amino acid transport                                                                              5           83         3.4              0.048
  Localization within membrane                                                                      5           83         3.4              0.048

*DFLAT, Developmental FunctionaL Annotation at Tufts (DFLAT) database. Table are the same columns as in the legend of [Table 2](#T2){ref-type="table"}*.

Enrichment analyses were then expanded to canonical pathways and gene sets from the Molecular Signatures Database (MSigDB), and 53 such pathways were found to be associated with advancing gestation. These included the Reactome database ([@B47]) pathways: *immune system, adaptive immune system, cytokine signaling in immune system*, and *immunoregulatory interactions between a lymphoid cell and a non-lymphoid cell*, as well as the KEGG database ([@B48]) pathways: *natural killer cell-mediated cytotoxicity, antigen processing and presentation*, and *graft vs. host disease* ([Table 4](#T4){ref-type="table"}).

###### 

MSigDB canonical pathways enriched in genes differentially expressed with gestational age.

  **MSIGDB gene set name**                                                                            **Count**   **Size**   **Odds ratio**   ***q***
  --------------------------------------------------------------------------------------------------- ----------- ---------- ---------------- ---------
  Reactome immune system                                                                              61          877        4.2              0.000
  Reactome adaptive immune system                                                                     38          510        4.4              0.000
  Reactome immunoregulatory interactions between a lymphoid and a non-lymphoid cell                   12          63         12.5             0.000
  KEGG graft vs. host disease                                                                         10          39         18.2             0.000
  KEGG natural killer cell mediated cytotoxicity                                                      16          127        7.7              0.000
  KEGG antigen processing and presentation                                                            13          79         10.4             0.000
  Reactome interferon signaling                                                                       16          149        6.4              0.000
  BIOCARTA AHSP pathway                                                                               6           13         45               0.000
  KEGG hematopoietic cell lineage                                                                     12          87         8.5              0.000
  Reactome interferon gamma signaling                                                                 10          61         10.3             0.000
  Reactome interferon alpha beta signaling                                                            9           57         9.9              0.000
  Reactome cytokine signaling in immune system                                                        18          257        4                0.000
  Reactome metabolism of porphyrins                                                                   5           14         29.1             0.000
  Biocarta TOB1 pathway                                                                               5           19         18.7             0.000
  PID HIF1 TF Pathway                                                                                 8           66         7.3              0.001
  Reactome Class I MHC mediated antigen processing presentation                                       15          234        3.6              0.001
  KEGG allograft rejection                                                                            6           37         10.1             0.001
  PID HDAC CLASS III pathway                                                                          5           25         13.1             0.001
  PID SMAD2 3NUCLEAR Pathway                                                                          8           81         5.8              0.002
  KEGG ABC transporters                                                                               6           44         8.3              0.002
  PID IL4 2 pathway                                                                                   7           63         6.6              0.002
  PID IL12 2 pathway                                                                                  7           63         6.6              0.002
  Reactome L1CAM interactions                                                                         8           84         5.5              0.002
  PID TNF pathway                                                                                     6           46         7.9              0.002
  KEGG asthma                                                                                         5           30         10.5             0.002
  KEGG autoimmune thyroid disease                                                                     6           47         7.7              0.002
  KEGG porphyrin and chlorophyll metabolism                                                           5           32         9.7              0.003
  PID IL12 STAT4 pathway                                                                              5           33         9.3              0.003
  Reactome antigen processing cross presentation                                                      7           73         5.6              0.003
  Reactome transcriptional activity of SMAD2 SMAD3 SMAD4 heterotrimer                                 5           36         8.4              0.004
  Reactome signaling by TGF beta receptor complex                                                     6           59         5.9              0.006
  PID CD8 TCR downstream pathway                                                                      6           60         5.8              0.006
  PID FCER1 pathway                                                                                   6           61         5.7              0.006
  KEGG T cell receptor signaling pathway                                                              8           108        4.2              0.006
  Reactome costimulation by the CD28 family                                                           6           62         5.6              0.007
  KEGG type I diabetes mellitus                                                                       5           43         6.9              0.007
  Reactome nucleotide binding domain leucine rich repeat containing receptor NLR signaling pathways   5           44         6.7              0.008
  Reactome apoptosis                                                                                  9           144        3.5              0.009
  Reactome signaling by the B cell receptor BCR                                                       8           121        3.7              0.010
  KEGG B cell receptor signaling pathway                                                              6           75         4.6              0.013
  KEGG amyotrophic lateral sclerosis ALS                                                              5           53         5.5              0.013
  PID MYC ACTIV pathway                                                                               6           77         4.4              0.014
  KEGG ubiquitin mediated proteolysis                                                                 8           133        3.4              0.015
  KEGG apoptosis                                                                                      6           86         3.9              0.019
  KEGG pancreatic cancer                                                                              5           70         4                0.031
  KEGG viral myocarditis                                                                              5           70         4                0.031
  Reactome metabolism of nucleotides                                                                  5           72         3.9              0.033
  KEGG chronic myeloid leukemia                                                                       5           73         3.8              0.034
  Reactome signaling by EGFR in cancer                                                                6           103        3.2              0.036
  Reactome signaling by SCF kit                                                                       5           75         3.7              0.036
  PID p73 pathway                                                                                     5           79         3.5              0.040
  Reactome response to elevated platelet cytosolic Ca2                                                5           80         3.5              0.040
  Reactome cell surface interactions at the vascular wall                                             5           83         3.4              0.044

*MSigDB, Molecular Signatures Database. Table columns as in legend of [Table 2](#T2){ref-type="table"}*.

We then aimed at determining the origin of observed transcriptional activity by using the GNF Gene Expression Atlas to define genes predominantly expressed in specific human tissue or cell types, as previously described ([@B41]). This analysis revealed that gene sets specific to CD4+ and CD8+ T cells, CD71+ erythroid cells, CD105+ endothelial cells, and CD56+ NK cells, among others, were over-represented among the mRNAs that were modulated during gestation (*q* \< 0.05) ([Table 5](#T5){ref-type="table"}). In addition, genes reported to be specific to fetal organs (liver, lung, and brain) and the placenta were also enriched among significant genes (*q* \< 0.05) ([Table 5](#T5){ref-type="table"}). These data show that maternal and fetal cell-specific transcripts found in the maternal circulation are being modulated with advancing gestation.

###### 

Tissue or cell type-specific gene sets enriched in genes differentially expressed with gestational age.

  **Tissue/cell type**                       **Count**   **Size**   **Odds ratio**   ***q***
  ------------------------------------------ ----------- ---------- ---------------- ---------
  CD71+ early erythroid cells                80          198        40.4             0.000
  Bone marrow                                45          102        44.2             0.000
  CD105+ endothelial cells                   34          142        17.3             0.000
  CD56+ NK cells                             33          279        7.3              0.000
  CD8+ T cells                               28          215        8.1              0.000
  CD4+ T cells                               27          207        8.1              0.000
  Fetal liver                                22          129        11.1             0.000
  Tonsil                                     17          91         12.3             0.000
  CD19+ B cells (neg. sel.)                  23          217        6.4              0.000
  BDCA4+ dentritic cells                     25          269        5.5              0.000
  Trachea                                    12          74         10.2             0.000
  Whole blood                                24          322        4.3              0.000
  Burkitt\'s lymphoma cells (Daudi)          13          103        7.7              0.000
  CD34+ cells                                14          157        5.2              0.000
  Salivary gland                             8           51         9.8              0.000
  HL-60 promyelocytic leukemia cells         8           58         8.4              0.000
  721-B-lymphoblasts                         18          299        3.4              0.000
  CD33+ myeloid cells                        19          335        3.2              0.000
  Lymph node                                 8           64         7.5              0.000
  Thymus                                     9           85         6.2              0.000
  Bronchial epithelial cells                 11          141        4.5              0.000
  Colorectal adenocarcinoma                  8           83         5.6              0.000
  Burkitt\'s lymphoma cells (Raji)           9           110        4.7              0.001
  Colon                                      10          138        4.1              0.001
  CD14+ monocytes                            15          285        2.9              0.001
  Pancreatic islet                           8           117        3.9              0.004
  Fetal lung                                 7           111        3.5              0.011
  Prostate                                   7           114        3.4              0.013
  K-562 chronic myelogenous leukemia cells   4           42         5.5              0.016
  Fetal brain                                9           186        2.7              0.018
  Placenta                                   10          233        2.4              0.026
  Ovary                                      3           29         6                0.032
  Small intestine                            7           142        2.7              0.034

*Gene sets are defined based on average expression in a given tissue/cell type \>30 time the median expression across all other biotypes cataloged in the GNF Gene Expression Atlas (see Methods). Table columns are the same as in the legend of [Table 2](#T2){ref-type="table"}*.

The average abundance of cell type-specific gene sets recently defined using single-cell transcriptomics ([@B42]) were also analyzed for systematic changes with gestational age at blood draw in our cohort. This analysis revealed that expression of mRNAs specific to three cell subtypes were dynamically altered throughout normal pregnancy: (1) the T-cell-specific mRNA signature decreased from the first to second trimester, followed by a subsequent increase during the third trimester ([Figure 4A](#F4){ref-type="fig"}); (2) the B-cell-specific mRNA signature decreased steadily throughout gestation ([Figure 4B](#F4){ref-type="fig"}); and (3) the expression of genes specific to nucleated erythroid cells (*HBZ, ALAS2*, and *AHSP*) significantly increased as gestation progressed ([Figure 4C](#F4){ref-type="fig"}). These findings demonstrate, for the first time, that single-cell RNA-Seq-derived signatures of erythroid cells change throughout normal gestation in maternal whole blood, while trends found for T cells and B cells were similar to those reported in whole blood ([@B49]) and by using cell-free RNA analysis ([@B42]).

![Meta-gene expression of specific cell types differentially regulated throughout normal pregnancy. The average expression of genes defined as specific for **(A)** T cell, **(B)** B cell, and **(C)** erythroid cell populations by Tsang et al. ([@B42]) are shown as a function of gestation. Blue lines correspond to the average expression estimated by linear mixed-effects models. The fold change in expression from 10 to 40 weeks was 1.2 for T cells and B cells and 1.6 for erythroid cells (all, *p* \< 0.001).](fimmu-10-02863-g0004){#F4}

Correlation Between the Cellular Transcriptome and Plasma Proteome Throughout Normal Pregnancy
----------------------------------------------------------------------------------------------

Transcription does not always correlate with protein translation ([@B50], [@B51]). Therefore, we investigated the correlation between the mRNAs that were modulated throughout gestation and their corresponding protein abundance. Maternal plasma abundance of 1,125 proteins in 71 samples collected from 16 of the women included in the current study was previously reported ([@B43], [@B52]). First, we assessed the mRNA-protein correlation for 53 of the 614 transcript clusters that changed throughout gestation and for which abundance data for the corresponding protein were available. These correlations were compared to those of 1,011 mRNA-protein pairs that did not change with gestation. The mRNA-protein correlations were significantly higher for transcripts that changed throughout gestation compared to those that did not (Wilcoxon test for comparing t-scores of the linear regression slope obtained by linear mixed-effects models for each mRNA-protein pair, *p* = 0.01) ([Figure 5](#F5){ref-type="fig"}). Among the 53 transcripts that changed throughout gestation, *BPI, IGHG1, CXCL10, GNLY*, and *GZMA* had a significant mRNA-protein correlation as assessed by both linear mixed-effects models and a naïve Spearman correlation test (*q* \< 0.05 for both analyses) ([Figure 6](#F6){ref-type="fig"}). Notably, two of these genes (*GNLY* and *GZMA*) were included in the T-cell-specific mRNA signature that was modulated overall throughout gestation.

![Distribution of mRNA-protein correlation *t*-scores. The correlation between mRNA and protein abundance was assessed by linear mixed-effects models using data collected from 71 samples provided by 16 women. The distribution of t-scores for the linear correlation slope is shown for 51 mRNAs differentially expressed with gestation and 1011 mRNAs that were not differentially expressed.](fimmu-10-02863-g0005){#F5}

![Correlation between cellular transcriptome and maternal plasma proteome throughout normal pregnancy. Aptamer-based protein abundance measurements are plotted against mRNA expression. R: naïve Spearman correlation coefficient; p: likelihood ratio test *p*-value from linear mixed-effects models assessing the linear correlation accounting for repeated measurements from the same subjects.](fimmu-10-02863-g0006){#F6}

Discussion {#s4}
==========

Principal Findings of the Study
-------------------------------

\(1\) Chromosome 14 was the most enriched in transcripts differentially expressed throughout normal pregnancy (51/613 mRNA clusters). (2) Among the most differentially expressed genes (*q* \< 0.1, and fold change \> 1.5), three distinct longitudinal patterns were observed: (i) steady increase throughout gestation (89 genes), (ii) steady decrease throughout gestation (12 genes), or (iii) decrease prior to mid-gestation followed by an increase (11 genes). (3) Sixteen genes, most of them related to host immune response mediators (e.g., *MMP8, DEFA1B, DEFA4, LTF*), displayed \>2-fold change in expression and steadily increased from 10 to 40 weeks of gestation. (4) Approximately 300 biological processes and 53 pathways, many of which were related to immunity and inflammation, were enriched among the differentially expressed genes (*q* \< 0.05). (5) Genes changing with gestation were among those specific to T cells, B cells, CD71+ erythroid cells, natural killer cells, and endothelial cells, as defined based on the GNF Gene Expression Atlas. (6) The meta-gene expression of mRNA signatures for T cells, B cells, and erythrocyte cells were significantly modulated throughout gestation, each following a unique pattern (*p* \< 0.05). (7) The correlation between mRNA and protein abundance was higher for mRNAs that were differentially expressed throughout gestation than for those that were not (*p* = 0.01). (8) Significant and positive mRNA-protein correlations (*q* \< 0.05) were observed for *BPI, IGHG1, CXCL10*, and two members of the T-cell mRNA signature (*GNLY, GZMA*). The expression trends and variability in expression of individual genes and meta-genes in normal pregnancy (nomograms) derived herein will be the basis for future studies aiming at developing biomarkers for obstetrical disease.

Transcriptomic Changes During Pregnancy
---------------------------------------

Previous studies have investigated the cellular ([@B53], [@B54]) and cell-free ([@B55]) transcriptome in the maternal circulation at different time points during normal pregnancy using either 3-prime-end biased microarrays or targeted approaches. The current study, however, is the first to quantify at exon-level resolution the cellular transcriptome during normal pregnancy in up to six samples per pregnancy. More than one-half (54%, 277/514) of the unique differentially expressed genes identified herein were also among the 2,321 genes (*q* \< 0.1) reported by Heng et al. ([@B54]) to change from 17--23 to 27--33 weeks of gestation. Similarly, 47% (242/514) of the genes found in this study were among the 3,830 genes reported by Al-Garawi et al. ([@B53]) as changing from 10--18 to 30--38 weeks. The overlap between the genes reported as differentially expressed in these two studies and those identified herein is significant (Fisher\'s exact test *p* \< 0.0001 for both). However, unlike in the two previous studies involving a pair of samples from each woman, the availability of four to six longitudinal samples per patient in this study enabled us to capture more complex expression trajectories in the window of 10--40 weeks of gestation, and to identify distinct clusters of such gene expression trajectories.

Compared to another recent study by Ngo et al. ([@B55]) that involved more frequent sampling than used herein, our study has the advantage of an unbiased assessment of the whole cellular transcriptome as opposed to a targeted assessment of genes that are placenta-, immune-, and fetal liver-specific. Of note, among the 14 immune-specific cell-free mRNAs selected by Ngo et al. ([@B55]) as best predictors of gestational age at blood draw, 11 were also identified in our study, with *CEACAM8, DEFA4, LTF*, and *MMP8* being among those with highest fold change. Although our results are somewhat consistent with those reported by Ngo et al. ([@B55]), it should be noted that cellular and cell-free transcripts can follow different patterns in similar physiological and pathological processes ([@B56]).

Correlations Between the Cellular Transcriptome and the Plasma Proteome Throughout Normal Pregnancy
---------------------------------------------------------------------------------------------------

The finding that the maternal transcriptome features inflammation-related processes and pathways that are being activated in preparation for labor at term is in agreement with our previous studies in gestational tissues \[cervix ([@B57]), myometrium ([@B58]), membranes ([@B59])\] and a similar longitudinal study of the maternal plasma proteome ([@B52]). In addition to finding several common biological processes that are modulated in both the maternal plasma proteome and cellular transcriptome (such as *defense response, defense response to bacterium, defense response to fungus, regulation of bone resorption, leukocyte migration*) we assessed, for the first time, the extent of the agreement in whole blood mRNA and protein changes with gestation in the same set of samples. Although the correlations between mRNA and protein expression reported in the literature are notoriously poor, recent studies showed that mRNA-protein correlation is higher for mRNAs that are differentially expressed in a given condition than for those that are not ([@B51]). Our finding that the correlation of mRNA-protein pairs is higher for transcripts changing with gestation than those who do not is therefore consistent with previous observations ([@B51]).

T Cells in the Maternal Circulation During Normal Pregnancy
-----------------------------------------------------------

Maternal T cells are implicated in the physiological processes occurring throughout gestation ([@B60]--[@B63]). Effector and activated T cells are found at the maternal-fetal interface before ([@B64]--[@B70]) and during ([@B71]--[@B73]) spontaneous labor at term, and these cells are associated with the timing of term parturition ([@B74]). Effector T cells are also found in the maternal blood prior to Shah et al. ([@B75]) and during ([@B76]) labor at term. In the current study, we demonstrated that the T-cell-specific mRNA expression in the maternal circulation was decreased prior to mid-gestation but upregulated from mid-gestation until term. Moreover, for two of 19 genes of this signature, there was a significant correlation between cellular mRNA and plasma proteomic profiles; this is consistent with recent cytomic and proteomic studies in the maternal circulation ([@B77], [@B78]). In addition, we recently showed the same u-shaped pattern of expression for the T-cell mRNA signature during gestation in a smaller set of patients profiled with RNA-Seq and qRT-PCR platforms ([@B49]). Together, these findings illustrate the importance of maternal T cells during normal pregnancy.

Alteration of systemic T-cell populations has also been implicated in preterm parturition ([@B79]--[@B81]), especially since aberrant activation of these cells can induce the onset of preterm labor ([@B82], [@B83]). On the other hand, the absence of T cells in a mouse model caused an increased susceptibility to endotoxin-induced preterm birth, which was reversed by adoptive transfer of CD4+ T cells ([@B84]). From a histopathological standpoint, T cells are detected in placental lesions related to maternal anti-fetal rejection such as villitis of unknown etiology ([@B85]--[@B87]), chronic chorioamnionitis ([@B88]), and chronic deciduitis ([@B89]), which have also been linked to the onset of term and preterm labor ([@B88], [@B90]--[@B94]). The chronic nature ([@B95], [@B96]) of these lesions has led our group to propose them as indicators of maternal anti-fetal rejection, which can lead to preterm labor or even fetal death ([@B86], [@B90], [@B93], [@B94], [@B97]--[@B100]). Future studies are needed to establish whether the early detection of T-cell alterations in the maternal circulation may identify pregnancies at risk for obstetrical disease such as preterm labor/birth and fetal death.

B Cells in the Maternal Circulation During Normal Pregnancy
-----------------------------------------------------------

Several studies have suggested a role for B cells in the maintenance and success of pregnancy ([@B101]--[@B106]). Circulating CD5+ (B1) B cells were shown to decrease during pregnancy, only returning to normal levels after parturition ([@B107]). This finding was later shown to occur in mice, where a decreased influx of newly generated B cells to the blood and spleen was observed while mature B cells were increased in uterine-draining lymph nodes ([@B108]). An expansion of marginal zone B cells also ensued ([@B108], [@B109]), which was proposed to participate in the production of protective antibodies during pregnancy ([@B109], [@B110]). Accordingly, maternal serum antibody concentrations increased concomitantly with B-cell population changes ([@B109]), possibly as a result of the anti-inflammatory microenvironment maintained at the maternal-fetal interface throughout most of pregnancy ([@B111]). Such antibody production has been considered the primary contribution of B cells to maternal-fetal tolerance during pregnancy ([@B101]).

Interleukin-10-producing regulatory B cells (Bregs) have also been described as important players during pregnancy ([@B112], [@B113]). Such adaptive immune cells increased in normal pregnancy in an hCG-dependent manner ([@B113], [@B114]) and suppressed effector T-cell cytokine production ([@B113]). Trophoblast cells facilitated the conversion of IL10-deficient B cells into IL10-expressing B cells ([@B114]), which is in line with a previous report showing that the adoptive transfer of Bregs restored maternal-fetal tolerance ([@B112]). Indeed, pregnant women treated with the B-cell-depleting treatment rituximab had a higher occurrence of pregnancy loss ([@B115]), although further investigation of this phenomenon is warranted ([@B116]).

In the current study, we showed that the B-cell-specific mRNA signature moderately decreased throughout pregnancy. Our observations correspond to a previous report indicating that the majority of maternal peripheral B-cell subsets are reduced in late gestation compared to the non-pregnant state ([@B117]), whereas Bregs are upregulated ([@B117]). The combined effects of such dynamic changes on the overall circulating B-cell mRNA signature are therefore minimal, as we have demonstrated here. Taken together, these findings suggest that, while total maternal peripheral B cells are mostly maintained, subset-specific changes occur throughout pregnancy.

Erythroid Cells in the Maternal Circulation During Normal Pregnancy
-------------------------------------------------------------------

A constant bi-directional trafficking of maternal and fetal cells occurs during normal pregnancy ([@B118]--[@B124]). Indeed, cell-free fetal DNA is present in the maternal circulation throughout normal pregnancy ([@B125]--[@B132]) and its levels increased from mid to late gestation ([@B128], [@B133]--[@B140]). Increased concentrations of cell-free fetal DNA or numbers of fetal cells in the maternal circulation (fetal microchimerism) have been linked to pregnancy complications such as preterm labor ([@B141]--[@B145]), preeclampsia ([@B146]--[@B150]), and intrauterine growth restriction ([@B149], [@B151], [@B152]). In addition, sequencing cell-free fetal DNA in the maternal circulation may serve for non-invasive prenatal testing ([@B153]). Therefore, determining the impact that fetal cells and their released products (e.g., cell-free fetal DNA) may have on maternal health is critical, given that such cells can remain in the maternal circulation for decades ([@B153], [@B154]).

Fetal nucleated erythroid cells have been detected in the maternal blood ([@B121], [@B155], [@B156]) where they may be a source of cell-free fetal DNA ([@B155]). Previous reports showed that neonatal CD71+ erythroid cells have immunomodulatory functions on cord blood leukocytes ([@B157]--[@B159]), and that their direct contact with maternal peripheral immune cells increases the secretion of pro-inflammatory mediators by such cells ([@B159]). Therefore, it is likely that the trafficking of CD71+ erythroid cells from the fetus into the mother directly affects maternal immune responses ([@B159]). Nucleated erythroid cells have also been described in the placenta, where their presence is correlated with the number of such cells in the cord blood ([@B160]), and these cells also display immunomodulatory properties *in vitro* ([@B161]).

Herein, we showed that the erythroid cell-specific mRNA signature was upregulated throughout gestation in the maternal circulation. This finding is in line with previous reports showing that fetal microchimerism increases during pregnancy ([@B162], [@B163]). In addition, a recent study showed that CD71+ erythroid cells are increased in the maternal circulation throughout gestation, peaking during the third trimester and falling to baseline levels after delivery ([@B164]). Together, these findings illustrate that erythroid cells, most likely of fetal origin, are present in the maternal circulation and their transcriptome is modulated as gestation progresses. These data provide a possible mechanism whereby the developing fetus can modulate maternal immunity.

Conclusion {#s5}
==========

We have reported herein a detailed characterization of the longitudinal maternal whole blood transcriptomic changes in normal pregnancy. We have shown that these changes are genome-wide, yet we found that chromosome 14 was particularly enriched in genes modulated with advancing gestation. There was a significant overlap in expression changes described herein with those previously reported in whole blood analyses based on only two time points, while some of the most strongly modulated mRNAs identified herein were also previously reported as the best predictors of gestational age in cell-free RNA analyses of maternal blood. Our systems biology approach to the interpretation of these expression changes in the maternal cellular transcriptome during pregnancy revealed significant longitudinal patterns of expression for immune-related gene sets, such as those specific to T cells, B cells, and erythroid cells. Moreover, for the first time, we demonstrated positive correlations between the cellular transcriptome and plasma proteome for specific genes, including those expressed by T cells. The expression trajectories of protein coding and non-coding transcripts in normal pregnancy described herein may serve as references and hence enable the discovery of biomarkers for obstetrical disease.
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###### 

Differential gene expression with gestational age. Each row corresponds to one of the 614 transcript clusters associated with gestational age. ID, Affymetrix transcript cluster identifier; SYMBOL, gene symbol; ENTREZ, Entrez gene database identifier; Name, Gene name; mRNA, mRNA identifier; Source, mRNA identifier source; locus.type, coding vs. non-protein coding assignment; Chromosome, chromosome number; strand, chromosome strand; start/stop, genomic coordinate start and stop for the transcript cluster; *p*-value, significance value for the polynomial relation between log gene expression and gestational age; FC, log~2~ fold change representing the log~2~ ratio of the highest and lowest fitted value from 10 to 40 weeks of gestation (see [Figure 3](#F3){ref-type="fig"}). The sign is positive if value at 40 weeks is higher than the value at 10 weeks, and negative otherwise. adj.P.Value, False discovery adjusted *p*-value.
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Click here for additional data file.

###### 

Longitudinal gene expression profiles of genes associated with gestational age. Each figure shows data for one of the 614 transcript clusters associated with gestational age. The y-axis represents the log~2~ normalized gene expression, while the x-axis represents gestational age (weeks). Each line corresponds to one patient and each dot to one sample. The thick blue line represents the linear mixed effects model fit. The title in each plot, represents the transcript cluster identifier, gene symbol, gene name, *p*-value, and fold change. The meanings of these annotations are as in the legend of [Supplementary File 1](#SM1){ref-type="supplementary-material"}.
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